clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Fibrosis D005355 23 associated lipids
Periodontitis D010518 22 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Ischemia D007511 18 associated lipids
Dermatomycoses D003881 17 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Synovitis D013585 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Radiation Injuries D011832 14 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Urticaria D014581 13 associated lipids
Rosacea D012393 13 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Otitis Media D010033 12 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Influenza, Human D007251 11 associated lipids
Dyspnea D004417 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Pancreatitis D010195 10 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Hemophilia A D006467 10 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Urethritis D014526 9 associated lipids
Urination Disorders D014555 9 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Velu PP et al. Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. 2016 Scott Med J pmid:27872397
Noh HM et al. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. 2016 Korean J Gastroenterol pmid:27871162
Yazdanbakhsh AR et al. Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. 2016 Water Environ. Res. pmid:28661328
Fan W et al. An unusual case of folliculitis spinulosa decalvans. 2016 Cutis pmid:27814407
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Sancak S et al. Intestinal blood flow by Doppler ultrasound: the impact of clarithromycin treatment for feeding intolerance in preterm neonates. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26135789
Uehara H et al. Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin. 2016 Curr. Eye Res. pmid:26125497
Ohe M et al. A case of lupus nephritis treated with clarithromycin, tacrolimus, and glucocorticoids. 2016 Kaohsiung J. Med. Sci. pmid:27638410
Phaw NA and Tsai HH Eosinophilic gastroenteritis: a challenge to diagnose and treat. 2016 BMJ Case Rep pmid:27613263
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Huh CW et al. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. 2016 PLoS ONE pmid:27588679
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Cosme A et al. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. 2016 Helicobacter pmid:25982426
Zemali N et al. Helicobacter pylori resistance to clarithromycin in Reunion Island. 2016 Med Mal Infect pmid:27427280
Ozeki K et al. Association of Hay Fever with the Failure of Helicobacter pylori Primary Eradication. 2016 Intern. Med. pmid:27374672
Campillo A et al. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. 2016 Med Clin (Barc) pmid:27374029
Khashei R et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. 2016 APMIS pmid:27357065
Alarcón-Millán J et al. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis. 2016 Infect. Genet. Evol. pmid:27355861
Khonche A et al. Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. 2016 Drug Res (Stuttg) pmid:27351245
Büchsel M et al. A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. 2016 Diagn. Microbiol. Infect. Dis. pmid:27342785
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Abd-Elsalam S et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. 2016 Medicine (Baltimore) pmid:27310977
De Francesco V et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. 2016 J Gastrointestin Liver Dis pmid:27308644
Garcia de Carvalho NF et al. Resazurin Microtiter Assay for Clarithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group. 2016 J. Clin. Lab. Anal. pmid:27169515
Schuster S et al. Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. 2016 Antimicrob. Agents Chemother. pmid:27161641
Oberhofer E [Quadruple therapy is more effective against H. pylori]. 2016 MMW Fortschr Med pmid:27155683
Mayor S Short term increase in neuropsychiatric events is seen with H pylori treatment containing clarithromycin. 2016 BMJ pmid:27143325
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Wong AY et al. Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin. 2016 JAMA Intern Med pmid:27136661
Zollner-Schwetz I et al. Primary resistance of Helicobacter pylori is still low in Southern Austria. 2016 Int. J. Med. Microbiol. pmid:27134190
Georgopoulos SD et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. 2016 Eur. J. Intern. Med. pmid:27134145
Kim JS et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. 2016 Gut Liver pmid:27114421
Manniello MD et al. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. 2016 Eur J Pharm Biopharm pmid:27106605
Li M et al. Inducible Expression of both ermB and ermT Conferred High Macrolide Resistance in Streptococcus gallolyticus subsp. pasteurianus Isolates in China. 2016 Int J Mol Sci pmid:27669217
Shichijo S et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. 2016 Gastrointest. Endosc. pmid:26995689
Radzikowska E et al. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. 2016 Adv. Exp. Med. Biol. pmid:26987326
Wu DC et al. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. 2016 Medicine (Baltimore) pmid:26986096
Swaminathan A et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. 2016 Int. J. Tuberc. Lung Dis. pmid:26970156
Wong IC Author's reply to Blake. 2016 BMJ pmid:26957514
Todo K et al. Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female. 2016 Ann. Hematol. pmid:26957356
Iyer G and Alexander GC Editorialists' reply to Blake. 2016 BMJ pmid:26957321
Blake Z Study provides insufficient evidence of a link between clarithromycin and myocardial infarction. 2016 BMJ pmid:26955978
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Ji Z et al. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. 2016 Medicine (Baltimore) pmid:26937912
Murakami K et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. 2016 Gut pmid:26935876
Park JY et al. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. 2016 Dig. Dis. Sci. pmid:26923948
Trac MH et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 2016 CMAJ pmid:26903359
Fralick M et al. Bleeding associated with coadministration of rivaroxaban and clarithromycin. 2016 CMAJ pmid:26811362
Berlin S et al. Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. 2016 Mol. Pharm. pmid:26808255
Sun H et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014]. 2016 Zhonghua Jie He He Hu Xi Za Zhi pmid:26792053
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Raymond J et al. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. 2016 Scand. J. Gastroenterol. pmid:26784882
Kefeli A et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. 2016 Bosn J Basic Med Sci pmid:26773183
Iyer G and Alexander GC Cardiovascular risks associated with clarithromycin. 2016 BMJ pmid:26769796
Wong AY et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. 2016 BMJ pmid:26768836
Hirama T et al. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. 2016 J. Clin. Microbiol. pmid:26739154
Radheshi E et al. Postmortem diagnosis of anaphylaxis in presence of decompositional changes. 2016 J Forensic Leg Med pmid:26735898
Villain J et al. Acute toxicities of pharmaceuticals toward green algae. mode of action, biopharmaceutical drug disposition classification system and quantile regression models. 2016 Ecotoxicol. Environ. Saf. pmid:26590695
Geng S et al. Clarithromycin ion pair in a liposomal membrane to improve its stability and reduce its irritation caused by intravenous administration. 2016 Expert Opin Drug Deliv pmid:26588710
Eszik I et al. High dynamic range detection of Chlamydia trachomatis growth by direct quantitative PCR of the infected cells. 2016 J. Microbiol. Methods pmid:26578244
Jain SK et al. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori. 2016 AAPS PharmSciTech pmid:26566630
Di Giulio M et al. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. 2016 Scand. J. Gastroenterol. pmid:26554617
Djennane-Hadibi F et al. High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. 2016 Microb. Drug Resist. pmid:26554340
Chen CH et al. Mycobacterium abscessus complex bacteremia due to prostatitis after prostate biopsy. 2016 Indian J Tuberc pmid:27998503
Gehlot V et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. 2016 J Glob Antimicrob Resist pmid:27530837
Xuan SH et al. Detection of clarithromycin-resistant Helicobacter pylori in clinical specimens by molecular methods: A review. 2016 J Glob Antimicrob Resist pmid:27436390
Siddiqui TR et al. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. 2016 J Pak Med Assoc pmid:27339574
Lahmer T et al. Pseudallescheria boydii with Aspergillus fumigatus and Aspergillus terreus in a Critically Ill Hematopoietic Stem Cell Recipient with ARDS. 2016 Mycopathologia pmid:26455910
Lee J et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26441216
Shimizu T and Suzaki H Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. 2016 Auris Nasus Larynx pmid:26441370
Apostolopoulos P et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. 2016 Scand. J. Gastroenterol. pmid:26435055
Hollitt A et al. Cat scratch disease of the parotid gland. 2016 Arch. Dis. Child. pmid:26403943
Sprague J et al. Cutaneous infection with Mycobacterium kansasii in a patient with myelodysplastic syndrome and Sweet syndrome. 2015 Cutis pmid:26244358
Sharara AI et al. Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. 2015 Aliment. Pharmacol. Ther. pmid:26238584
Graham DY and Gisbert JP Letter: clarithromycin dose for H. pylori therapy remains unresolved. 2015 Aliment. Pharmacol. Ther. pmid:26238583
Chou HW et al. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. 2015 Clin. Infect. Dis. pmid:25409476
Jeong BH et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. 2015 Am. J. Respir. Crit. Care Med. pmid:25393520
Hill FJ et al. From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions. 2015 BMJ Case Rep pmid:26106178
Yu T et al. Study on clarithromycin lactobionate based dual selector systems for the enantioseparation of basic drugs in capillary electrophoresis. 2015 J Sep Sci pmid:26097042
Trotti LM et al. Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. 2015 Ann. Neurol. pmid:26094838
AktaÅŸ B et al. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. 2015 Eur J Gastroenterol Hepatol pmid:25919773
Mitsui Y et al. Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication. 2015 Clin J Gastroenterol pmid:25733031
Ben Chaabane N and Al-Adhba HS Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. 2015 Indian J Gastroenterol pmid:25721770
Townsell MY et al. Pathology in practice. Canine distemper virus disease in a dog. 2015 J. Am. Vet. Med. Assoc. pmid:25719842
Scherübl H et al. [What is new in treating Helicobacter pylori infection?]. 2015 Dtsch. Med. Wochenschr. pmid:25704525
Blix HS et al. Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? 2015 Epidemiol. Infect. pmid:25388750
Brown-Elliott BA et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group, based on in vitro clarithromycin susceptibility. 2015 J. Clin. Microbiol. pmid:25568437
Amiri M Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura. 2015 Glob J Health Sci pmid:26925898
Zhang L et al. [Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection]. 2015 Zhonghua Nei Ke Za Zhi pmid:26887366
Park JB et al. Modulation of microenvironmental pH and utilization of alkalizers in crystalline solid dispersion for enhanced solubility and stability of clarithromicin. 2015 Arch. Pharm. Res. pmid:25213008
Anton E et al. Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. 2015 Antimicrob. Agents Chemother. pmid:26711765
Winters N et al. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. 2015 Eur. Respir. J. pmid:26381514
John A et al. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection? 2015 Indian J Gastroenterol pmid:26541342
Mel-Hennawi D and Ahmed MR Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. 2015 J Laryngol Otol pmid:26521817
Parra D et al. In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. 2015 BMC Microbiol. pmid:26518881
Xing J et al. The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans. 2015 Anal. Chim. Acta pmid:26515003
Weiss S et al. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. 2015 Antimicrob. Agents Chemother. pmid:26392505
Agrawal V et al. A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. 2015 J Am Geriatr Soc pmid:26389998
Hauser G et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. 2015 Medicine (Baltimore) pmid:25929897